Cartesian Therapeutics, Inc. (RNAC) vs Surrozen, Inc. (SRZN)
A side-by-side comparison of Cartesian Therapeutics, Inc. and Surrozen, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
RNAC
Cartesian Therapeutics, Inc.
$6.75HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SRZN
Surrozen, Inc.
$26.37HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — RNAC vs SRZN
growth of $100 · dividends reinvested · last 6yRNAC -92.7% (-35.4%/yr)SRZN -80.8% (-24.0%/yr)SRZN compounded faster over this window
RNAC SRZN
RNAC vs SRZN: by the numbers
- •RNAC is the larger company ($198M vs $197M market cap).
- •Both run net losses; SRZN's is the smaller (-2885.33% vs -10422.48% net margin).
Metrics side by side
Valuation
| Metric | RNAC | SRZN |
|---|---|---|
| P/S ratio | 134.28 | 17.13 |
Profitability
| Metric | RNAC | SRZN |
|---|---|---|
| Gross margin | 100.00% | 84.56% |
| Operating margin | -3099.93% | -1210.58% |
| Net margin | -10422.48% | -2885.33% |
| ROIC | -33.10% | -41.61% |
Growth (annualized)
| Metric | RNAC | SRZN |
|---|---|---|
| Revenue CAGR (5Y) | -50.01% | N/A |
| Total return CAGR (5Y) | -44.03% | -20.80% |
Frequently asked
- How have RNAC and SRZN total returns compared?
- Over the past 5 years, RNAC delivered -44.03% and SRZN delivered -20.80% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.